AGK and triple-negative breast carcinoma: Considering that the role of AGK as a therapeutic target in triple-negative breast cancer has not been definitively established, we employed siRNA to knock down the AGK gene in the SK-BR-3 and MDA-MB-231 cell lines (Figure 1A).